Treatment Options for Platinum Resistant Ovarian Cancer - Webinar-Webinar Recording - Treatment Options for Platinum Resistant Ovarian Cancer

Video Transcription

Video Summary

The video is a webinar on the topic of treatment options for Platinum-Resistant Ovarian Cancer. The webinar is moderated by Dr. Kathleen Moore, a gynecological oncologist, and is supported in part by Immunogen. The speaker of the webinar is Dr. Ursula Matulonis, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute. <br /><br />Dr. Matulonis discusses the treatment options for platinum-resistant ovarian cancer and focuses on a recently FDA-approved medication-antibody conjugate called Mirvotuximab Sorasion. She explains that platinum-resistant ovarian cancer has been challenging to treat, often using single-agent chemotherapy with limited success. However, Mirvotuximab Sorasion has shown promising results, with a response rate of 32.4% and a median duration of response of 6.9 months. The drug targets folate receptor alpha (FR-alpha), which is elevated in most ovarian cancers. <br /><br />Dr. Matulonis also discusses the safety and tolerability of Mirvotuximab Sorasion, noting that the most common side effects are low-grade reversible ocular and gastrointestinal events. She emphasizes the importance of proactive management of ocular events, including baseline and regular ophthalmic exams, and the use of prophylactic medications to reduce the incidence and severity of infusion-related reactions. <br /><br />The webinar concludes by highlighting the ongoing research and potential future developments in the field of antibody drug conjugates for ovarian cancer treatment. The video provides valuable information for healthcare professionals involved in the management of platinum-resistant ovarian cancer.

Keywords

webinar

treatment options

Platinum-Resistant Ovarian Cancer

Mirvotuximab Sorasion

response rate

folate receptor alpha

antibody drug conjugates